Androgel makers fight for FTC to be cross-appellant

AbbVie and Besins Healthcare say they want the Federal Trade Commission to be designated the cross-appellant because this would be logical, not because it would limit the extent to which the agency could brief its side of the sham litigation case.

Get unlimited access to all Global Competition Review content